Accutane (Isotretinoin) Side Effects: Severity Distribution by Patient Phenotype

Print or save as PDFOpens the printable lab tracker and your print dialog. No sign-up.

What the labels report, and how often

Dry lips, dry skin, back pain, dry eye, joint pain, nosebleeds, headache and raised creatine kinase are among the reactions the Absorica label lists at an incidence of 5% or more [1]. Cheilitis and hypertriglyceridemia are the two it calls dose related [1]. The Accutane label says most adverse reactions in the clinical trials were reversible when therapy stopped, though some persisted [2].

On lipids, the Accutane label reports marked triglyceride elevation in about 25% of patients in clinical trials, a decrease in HDL in about 15% and a rise in cholesterol in about 7%, with triglycerides above 800 mg/dL reported. Those effects were reversible after the drug stopped, and some patients reversed triglyceride elevation with weight reduction, dietary fat and alcohol restriction, and a lower dose [2].

Which patients the label treats as higher risk

Diabetes, obesity, increased alcohol intake, and a lipid metabolism disorder or family history of one are the traits the Accutane label names. It calls for especially careful risk/benefit weighing in those patients and more frequent checks of lipids and blood sugar if treatment goes ahead [2]. The Absorica label requires a fasting lipid profile and liver function tests in all patients before treatment [1]. The Accutane label says blood lipids should be measured before the drug is given and then at intervals until the lipid response is established, which usually occurs within 4 weeks [2].

Psychiatric, eye and intracranial-pressure risks

Isotretinoin may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts and aggressive behavior, and the Accutane label says no mechanism has been established for these events [2]. The Absorica label directs prescribers to ask about prior psychiatric disorders before treatment and to assess for depression, mood disturbance, psychosis and aggression at each visit. It instructs patients or caregivers to stop the drug immediately and promptly contact their health care provider if any of these develop [1].

Both labels advise avoiding tetracyclines with isotretinoin, because isotretinoin has been associated with cases of intracranial hypertension (pseudotumor cerebri), some of which involved tetracyclines [1][2]. Dry eye and decreased night vision, which may persist, are listed ocular reactions. For visual symptoms, the Absorica label says to discontinue and refer for an ophthalmological exam [1].

Do higher doses carry more side effects?

In a double-blind trial of 150 patients with treatment-resistant nodulocystic acne, equal groups received 0.1, 0.5 or 1 mg/kg/day. Response did not differ significantly between doses, and the authors reported only minor differences in side effects and laboratory abnormalities, but 42% of the 0.1 mg/kg/day group needed retreatment [3]. A 2026 single-centre randomized trial of cumulative 120 versus 150 mg/kg found adverse events mild and comparable in both arms [4].

What patient surveys add, and what they cannot

In a cross-sectional survey from Syria of 377 people aged 15 and older, 89.1% had used isotretinoin. Of these, 309 reported side effects, and 189 (56.3% of isotretinoin users) reported psychological symptoms including anxiety, mood changes, depression or suicidal thoughts. In all, 19.9% stopped treatment because of adverse effects [5]. This is self-reported data from one country.

Reports to FDA's adverse event system have limits too. A report does not mean the drug caused the event, duplicate and incomplete reports exist, and the reports cannot be used to estimate how often an event occurs [6].